Literature DB >> 27479614

Trends in Prevalence of Chronic Kidney Disease in the United States.

Daniel Murphy1, Charles E McCulloch1, Feng Lin1, Tanushree Banerjee1, Jennifer L Bragg-Gresham1, Mark S Eberhardt1, Hal Morgenstern1, Meda E Pavkov1, Rajiv Saran1, Neil R Powe1, Chi-Yuan Hsu1.   

Abstract

Background: Trends in the prevalence of chronic kidney disease (CKD) are important for health care policy and planning. Objective: To update trends in CKD prevalence. Design: Repeated cross-sectional study. Setting: NHANES (National Health and Nutrition Examination Survey) for 1988 to 1994 and every 2 years from 1999 to 2012. Participants: Adults aged 20 years or older. Measurements: Chronic kidney disease (stages 3 and 4) was defined as an estimated glomerular filtration rate (eGFR) of 15 to 59 mL/min/1.73 m2, estimated with the Chronic Kidney Disease Epidemiology Collaboration equation from calibrated serum creatinine measurements. An expanded definition of CKD also included persons with an eGFR of at least 60 mL/min/1.73 m2 and a 1-time urine albumin-creatinine ratio of at least 30 mg/g.
Results: The unadjusted prevalence of stage 3 and 4 CKD increased from the late 1990s to the early 2000s. Since 2003 to 2004, however, the overall prevalence has largely stabilized (for example, 6.9% prevalence in 2003 to 2004 and in 2011 to 2012). There was little difference in adjusted prevalence of stage 3 and 4 CKD overall in 2003 to 2004 versus 2011 to 2012 after age, sex, race/ethnicity, and diabetes mellitus status were controlled for (P = 0.26). Lack of increase in CKD prevalence since the early 2000s was observed in most subgroups and with an expanded definition of CKD that included persons with higher eGFRs and albuminuria. Limitation: Serum creatinine and albuminuria were measured only once in each person.
Conclusion: In a reversal of prior trends, there has been no appreciable increase in the prevalence of stage 3 and 4 CKD in the U.S. population overall during the most recent decade. Primary Funding Source: American Society of Nephrology Foundation for Kidney Research Student Scholar Grant Program, Centers for Disease Control and Prevention, and National Institutes of Health.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27479614      PMCID: PMC5552458          DOI: 10.7326/M16-0273

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  33 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Antihypertensive medication use among US adults with hypertension.

Authors:  Qiuping Gu; Ryne Paulose-Ram; Charles Dillon; Vicki Burt
Journal:  Circulation       Date:  2006-01-03       Impact factor: 29.690

3.  Incidence of end-stage renal disease in patients with type 1 diabetes.

Authors:  Patrik Finne; Antti Reunanen; Svante Stenman; Per-Henrik Groop; Carola Grönhagen-Riska
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

4.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

Review 5.  Chronic kidney disease: the global challenge.

Authors:  A Meguid El Nahas; Aminu K Bello
Journal:  Lancet       Date:  2005 Jan 22-28       Impact factor: 79.321

6.  Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

7.  Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000.

Authors:  Josef Coresh; Danita Byrd-Holt; Brad C Astor; Josephine P Briggs; Paul W Eggers; David A Lacher; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

8.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

9.  Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States.

Authors:  Chi-Yuan Hsu; Feng Lin; Eric Vittinghoff; Michael G Shlipak
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

10.  The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency.

Authors:  Chi-yuan Hsu; Eric Vittinghoff; Feng Lin; Michael G Shlipak
Journal:  Ann Intern Med       Date:  2004-07-20       Impact factor: 25.391

View more
  185 in total

1.  Sex-Related Disparities in CKD Progression.

Authors:  Ana C Ricardo; Wei Yang; Daohang Sha; Lawrence J Appel; Jing Chen; Marie Krousel-Wood; Anjella Manoharan; Susan Steigerwalt; Jackson Wright; Mahboob Rahman; Sylvia E Rosas; Milda Saunders; Kumar Sharma; Martha L Daviglus; James P Lash
Journal:  J Am Soc Nephrol       Date:  2018-12-03       Impact factor: 10.121

2.  Pragmatic Randomized, Controlled Trial of Patient Navigators and Enhanced Personal Health Records in CKD.

Authors:  Sankar D Navaneethan; Stacey E Jolly; Jesse D Schold; Susana Arrigain; Georges Nakhoul; Victoria Konig; Jennifer Hyland; Yvette K Burrucker; Priscilla Davis Dann; Barbara H Tucky; John Sharp; Joseph V Nally
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-04       Impact factor: 8.237

3.  Obstructive Sleep Apnea, Other Sleep Characteristics, and Risk of CKD in the Atherosclerosis Risk in Communities Sleep Heart Health Study.

Authors:  Kelsie M Full; Chandra L Jackson; Casey M Rebholz; Kunihiro Matsushita; Pamela L Lutsey
Journal:  J Am Soc Nephrol       Date:  2020-06-26       Impact factor: 10.121

4.  Gait Abnormalities and the Risk of Falls in CKD.

Authors:  Jeannie Tran; Emmeline Ayers; Joe Verghese; Matthew K Abramowitz
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-24       Impact factor: 8.237

5.  Biological Variability of Estimated GFR and Albuminuria in CKD.

Authors:  Sushrut S Waikar; Casey M Rebholz; Zihe Zheng; Shelley Hurwitz; Chi-Yuan Hsu; Harold I Feldman; Dawei Xie; Kathleen D Liu; Theodore E Mifflin; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Joseph V Bonventre; Lesley A Inker; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2018-07-18       Impact factor: 8.860

6.  Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD.

Authors:  Dominik Steubl; Markus P Schneider; Heike Meiselbach; Jennifer Nadal; Matthias C Schmid; Turgay Saritas; Vera Krane; Claudia Sommerer; Seema Baid-Agrawal; Jakob Voelkl; Fruzsina Kotsis; Anna Köttgen; Kai-Uwe Eckardt; Jürgen E Scherberich
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-14       Impact factor: 8.237

7.  Black Americans' Perspectives of Barriers and Facilitators of Community Screening for Kidney Disease.

Authors:  Ebele M Umeukeje; Marcus G Wild; Saugar Maripuri; Teresa Davidson; Margaret Rutherford; Khaled Abdel-Kader; Julia Lewis; Consuelo H Wilkins; Kerri Cavanaugh
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 8.237

8.  Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker.

Authors:  Sidar Copur; Dimitrie Siriopol; Baris Afsar; Melis C Comert; Gizem Uzunkopru; Alan A Sag; Alberto Ortiz; Adrian Covic; Daniel H van Raalte; David Z Cherney; Peter Rossing; Mehmet Kanbay
Journal:  Acta Diabetol       Date:  2020-08-30       Impact factor: 4.280

9.  A comparison between 2017 FAS and 2012 CKD-EPI equations: a multi-center validation study in Chinese adult population.

Authors:  Zhenzhu Yong; Fen Li; Xiaohua Pei; Xun Liu; Dan Song; Xiaoxuan Zhang; Weihong Zhao
Journal:  Int Urol Nephrol       Date:  2018-10-24       Impact factor: 2.370

Review 10.  The global burden of chronic kidney disease: estimates, variability and pitfalls.

Authors:  Richard J Glassock; David G Warnock; Pierre Delanaye
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.